ClinicalOctober 7, 2026·22 min read

GLP-1 & Incretin Peptide Pipeline Tracker

Dated, sourced status table and readout log for every GLP-1, GIP, glucagon and amylin compound in trials or approved, with every estimand labelled.

Save

Five glowing research vials in a row on a dark lab surface, one per incretin drug class

This page is a running, dated record of the GLP-1 and incretin drug class: what each compound targets, where it sits in development, what its most recent trial reported, and which estimand that number comes from. It replaces the one-off trial-recap posts this site used to publish after every readout. Each row and each log entry links to a primary source, a journal article (with PMID) or the sponsor's own release. Last updated October 7, 2026.

Read the status table first for a snapshot, then the readouts log for the chronology. Weight-loss figures are only comparable across trials when the duration, population and estimand match, which they rarely do, so the "How to read trial numbers" section explains the labels used throughout. Community-sourced figures are not included here; every number is from a trial sponsor or a peer-reviewed publication.

Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Status table

Alphabetical. "Key readout" is the most recent or most pivotal weight result, with the estimand named. "TR" = treatment-regimen (treatment-policy) estimand; "EFF" = efficacy (trial-product) estimand; "PA" = placebo-adjusted. Sources are expanded in the References list.

Compound Sponsor Class / targets Highest phase Key readout Regulatory status (US) Source
Amycretin (zenagamtide) Novo Nordisk Unimolecular GLP-1 + amylin agonist Phase 3 (AMAZE programme initiated 2026) Up to -24.3% at 36 wk (60 mg sc) vs -1.1% placebo, Phase 1b/2a, n=125 Investigational Lancet 2025, PMID 40550231
Berobenatide (PF-3944 / MET-097i) Pfizer Ultra-long-acting GLP-1 agonist, monthly Phase 3 (VESPER programme, 2026) 12.3% PA at 28 wk on 4.8 mg monthly, Phase 2b VESPER-3 Investigational Pfizer release, Feb 2026
Bioglutide (NA-931) Biomed Industries Oral quadruple agonist (IGF-1, GLP-1, GIP, glucagon) Phase 2 complete; sponsor states Phase 3 next 13.8% at 13 wk on 150 mg/day, n=125 (sponsor abstract) Investigational NCT06564753; sponsor EASD 2025 release
CagriSema (cagrilintide + semaglutide) Novo Nordisk Amylin analogue + GLP-1 agonist, co-administered Phase 3 complete (REDEFINE / REIMAGINE); NDA filed Dec 2025 -20.4% TR at 68 wk vs -3.0% placebo, REDEFINE 1, n=3,417 (22.7% EFF per sponsor) NDA under FDA review; decision expected late 2026 NEJM 2025, PMID 40544433
Danuglipron Pfizer Oral small-molecule GLP-1 agonist Discontinued (April 14, 2025) No pivotal data; stopped after a case of possible drug-induced liver injury Discontinued STAT News, Apr 14, 2025
Eloralintide (LY3841136) Eli Lilly Selective amylin receptor agonist Phase 3 planned (sponsor) -20% EFF at 48 wk (9 mg) vs -0.4% placebo, Phase 2, n=263 Investigational Lancet 2025, PMID 41207310
EloraTZP (eloralintide + tirzepatide) Eli Lilly Amylin agonist + GIP/GLP-1 agonist Phase 2b complete; Phase 3 planned by end-2026 Up to -23.3% EFF at 48 wk vs -14.8% tirzepatide 15 mg alone, obesity + T2D, n=367 Investigational EASD 2026 presentation, Sept 30, 2026
Enicepatide (CT-388) Roche Biased GLP-1/GIP dual agonist Phase 3 (ENITH programme) 22.5% PA EFF (18.3% PA TR) at 48 wk on 24 mg, Phase 2, n=469 Investigational Roche release, Jan 27, 2026
Liraglutide Novo Nordisk GLP-1 agonist, daily Approved -8.0% at 56 wk vs -2.6% placebo, SCALE, n=3,731 FDA-approved (T2D; chronic weight management) NEJM 2015, PMID 26132939
Maridebart cafraglutide (MariTide) Amgen GLP-1 agonist / GIP antagonist antibody-peptide conjugate, monthly Phase 3 (MARITIME programme) -12.3% to -16.2% TR at 52 wk vs -2.5% placebo, Phase 2 obesity cohort, n=465 Investigational NEJM 2025, PMID 40549887
Mazdutide (IBI362) Innovent / Eli Lilly GLP-1/glucagon dual agonist Approved in China; US trials ongoing -14.01% at 48 wk (6 mg) vs +0.30% placebo, GLORY-1, n=610 Approved in China (weight management, June 27, 2025); not FDA-approved NEJM 2025, PMID 40421736
MBX 4291 MBX Biosciences Monthly GLP-1/GIP prodrug Phase 1 (MAD) ~7% at 8 wk, blinded preliminary, first MAD cohort n=8 (incl. 2 placebo) Investigational MBX release, May 11, 2026
Orforglipron Eli Lilly Oral small-molecule GLP-1 agonist (not a peptide) Approved -11.2% TR at 72 wk (36 mg) vs -2.1% placebo, ATTAIN-1, n=3,127 FDA-approved for weight management, April 1, 2026 NEJM 2025, PMID 40960239
Retatrutide (LY3437943) Eli Lilly GIP/GLP-1/glucagon triple agonist Phase 3 (TRIUMPH programme) 28.3% at 80 wk (12 mg) vs 2.2% placebo, TRIUMPH-1 sponsor headline, n=2,339; TRIUMPH-2 -18.8% TR Investigational; BLA planned Q1 2027 (sponsor) Lilly release, May 21, 2026; Lancet 2026, PMID 42810372
Semaglutide Novo Nordisk GLP-1 agonist, weekly (also oral) Approved; 7.2 mg dose studied -14.9% at 68 wk (2.4 mg) vs -2.4% placebo, STEP 1, n=1,961; 7.2 mg: -18.7% TR at 72 wk, STEP UP FDA-approved (T2D; chronic weight management) NEJM 2021, PMID 33567185; Lancet D&E 2025, PMID 40961952
Survodutide (BI 456906) Boehringer Ingelheim / Zealand GLP-1/glucagon dual agonist Phase 3 (SYNCHRONIZE programme) Up to 16.6% EFF at 76 wk vs 3.2% placebo, SYNCHRONIZE-1, n=725; T2D: -9.8% TR / 13.1% EFF, SYNCHRONIZE-2 Investigational; no announced US filing date BI release, Apr 28, 2026; NEJM 2026, PMID 42820639
Tirzepatide Eli Lilly GIP/GLP-1 dual agonist Approved -20.9% TR at 72 wk (15 mg) vs -3.1% placebo, SURMOUNT-1, n=2,539; -20.2% vs -13.7% semaglutide, SURMOUNT-5 FDA-approved (T2D; chronic weight management; CV-risk reduction in T2D added Aug 28, 2026) NEJM 2022, PMID 35658024; NEJM 2025, PMID 40353578
VK2735 Viking Therapeutics GLP-1/GIP dual agonist (sc and oral) Phase 3 (VANQUISH-1/-2 fully enrolled) Up to 14.7% at 13 wk (13.1% PA), VENTURE Phase 2; 22% PA at 33 wk on 17.5 mg weekly, maintenance study Investigational Viking releases, Jan 12 and Sept 22, 2026
CategoryWeight Loss & Metabolic Peptides
ClassGLP-1 agonist
GoalFat Loss

Compare Top Peptides

Best vendor pricing, COA verified, with active discount codes

RetatrutideCOA
Nura Peptide · $4.78/mg
thepeptidecatalog·30% off
Compare vendors
TirzepatideCOA
Nura Peptide · $3.17/mg
thepeptidecatalog·30% off
Compare vendors
SemaglutideCOA
Nura Peptide · $6.90/mg
thepeptidecatalog·30% off
Compare vendors
CagrilintideCOA
Nura Peptide · $10.00/mg
thepeptidecatalog·30% off
Compare vendors
SurvodutideCOA
EZ Peptides · $7.80/mg
thepeptidecatalog·10% off
Compare vendors

Readouts log

Reverse chronological. Each entry: date, trial, compound, population, arms, result with estimand label, source. Sponsor toplines are labelled as such; where a journal publication later reported a different estimand, both appear as separate dated entries.

A glowing pathway of connected nodes rising from dim grey to bright white-gold, representing a drug moving through trial phases

  • 2026-10-01 · SYNCHRONIZE-2 · survodutide — 752 adults with obesity and type 2 diabetes · 3.6 mg or 6.0 mg weekly vs placebo, 76 weeks · treatment-regimen estimand: -8.2% (3.6 mg), -9.8% (6.0 mg) vs -3.9% placebo; at least 5% loss in 57.6% / 64.5% / 35.1%; HbA1c -0.9 / -0.8 / -0.2 points from 7.4%; GI adverse events 72.8% / 77.7% / 38.6% · Wharton et al., NEJM (PMID 42820639). Sponsor release the same day reported "up to 13.1%" on the efficacy estimand vs 3.1% placebo (Boehringer Ingelheim, GlobeNewswire, Oct 1, 2026).
  • 2026-09-30 · EloraTZP Phase 2b (NCT06603571) · eloralintide + tirzepatide — 367 adults with obesity or overweight and type 2 diabetes, 10 arms, 48 weeks · efficacy estimand: -13.2% to -23.3% across combination tiers (top tier eloralintide 9 mg + tirzepatide 15 mg) vs -14.8% tirzepatide 15 mg alone, -8.2% to -12.3% eloralintide alone, -3.0% placebo; A1C -2.2 to -2.9 points from 8.1%; adverse-event discontinuation 10.8% to 27.0% on combination vs 2.9% on tirzepatide alone · EASD 2026 presentation (Lilly / EurekAlert release; HCPLive coverage).
  • 2026-09-29 · TRIUMPH-2 (journal publication) · retatrutide — 1,152 adults with obesity and type 2 diabetes · 4 mg, 9 mg or 12 mg weekly vs placebo, 80 weeks · treatment-regimen estimand: -11.9% / -16.8% / -18.8% vs -5.1% placebo; placebo-adjusted differences -6.9 / -11.8 / -13.8 points · Bellido et al., Lancet (PMID 42810372). The July 23 sponsor topline for the same trial led with 20.8% at 12 mg.
  • 2026-09-22 · VK2735-102 maintenance study · VK2735 — adults with obesity · 21-week weekly induction (final doses 15.0 to 22.5 mg) then 12-week re-randomisation to every-other-week, monthly or placebo · sponsor topline: 22% placebo-adjusted loss at week 33 on 17.5 mg weekly with no plateau; up to 97% of induction weight loss retained on every-other-week dosing and up to 90% on monthly dosing vs 61% on placebo; GI adverse events during maintenance similar to placebo · Viking Therapeutics release, Sept 22, 2026.
  • 2026-09-22 · CT-388-104 Phase 2 · enicepatide — 447 adults with type 2 diabetes and overweight or obesity · four dose arms vs placebo, 48 weeks · sponsor topline: HbA1c -2.65 points from 8.1% at the 24 mg dose; body weight -15.5% with no plateau; placebo-arm figures not released; adverse-event discontinuation 2.0% vs 0% placebo · Roche ad hoc announcement, Sept 22, 2026.
  • 2026-09-21 · REIMAGINE 5 and REDEFINE 9 · CagriSema — REIMAGINE 5: adults with type 2 diabetes inadequately controlled on metformin and/or an SGLT2 inhibitor, CagriSema 1.0 mg/1.0 mg vs tirzepatide 5 mg, 60-week endpoint · sponsor topline: -12.4% vs -9.1% (superiority met); HbA1c -1.71 vs -1.67 points (non-inferiority met). REDEFINE 9: adults with overweight or obesity, CagriSema 1.0/1.0 mg vs placebo, 68 weeks · -21.0% vs -2.0% · Novo Nordisk company announcement, Sept 21, 2026. Estimand not stated in the release.
  • 2026-08-28 · SURPASS-CVOT label expansion · tirzepatide — FDA approved tirzepatide to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk · based on 13,299 participants vs dulaglutide, median follow-up 210.1 weeks, MACE-3 hazard ratio 0.92 (95.3% CI 0.83 to 1.01), non-inferiority met · Lilly release, Aug 28, 2026; Nicholls et al., NEJM 2025 (PMID 41406444).
  • 2026-07-23 · TRIUMPH-2 and TRIUMPH-3 topline · retatrutide — TRIUMPH-2: adults with obesity and type 2 diabetes, up to 20.8% at 80 weeks. TRIUMPH-3: 1,949 adults with severe obesity and established cardiovascular disease, 9 mg or 12 mg vs placebo, 80 weeks, up to 22.6% (12 mg) vs 3.2% placebo; at 12 mg, triglycerides -37.0%, non-HDL cholesterol -16.5%, systolic blood pressure -9.3 mmHg, hsCRP -51.2% · sponsor headline figures; Lilly stated a BLA submission is planned for Q1 2027 · Lilly release, July 23, 2026.
  • 2026-06-06 · VESPER-3 detailed data (ADA 2026) · berobenatide (PF-3944) — adults with obesity or overweight without type 2 diabetes · four dose regimens vs placebo, 28-week primary endpoint · 12.3% placebo-adjusted weight loss on the 4.8 mg monthly arm; continued loss after transition from weekly to monthly dosing · Pfizer release, June 2026.
  • 2026-06-05 to 06-08 · ADA 2026 · enicepatide (CT388-103) detailed data — the January topline (below) presented in full: 24 mg, 48 weeks, 22.5% placebo-adjusted on the efficacy estimand; 18.3% placebo-adjusted on the treatment-regimen estimand; at least 20% loss in 47.8%, at least 30% in 26.1% · Roche, ADA 2026 (figures per the Jan 27, 2026 release).
  • 2026-05-21 · TRIUMPH-1 topline · retatrutide — 2,339 adults with obesity or overweight without type 2 diabetes · 4 mg, 9 mg or 12 mg weekly vs placebo, 80 weeks · sponsor headline: -19.0% / -25.9% / -28.3% vs -2.2% placebo; the release reports both efficacy and treatment-regimen estimands and states the peer-reviewed publication is pending · Lilly release, May 21, 2026.
  • 2026-05-11 · MBX 4291 Phase 1 · MBX 4291 — first multiple-ascending-dose cohort, n=8 including 2 placebo · 30 mg weekly x 4 then 120 mg · blinded preliminary: ~7% mean weight loss at 8 weeks (range 0 to 16%), placebo not yet separated out; pharmacokinetics consistent with monthly dosing · MBX Biosciences release, May 11, 2026.
  • 2026-04-28 · SYNCHRONIZE-1 topline · survodutide — 725 adults with obesity or overweight without type 2 diabetes · 3.6 mg or 6.0 mg weekly vs placebo, 76 weeks · efficacy estimand: up to 16.6% vs 3.2% placebo; at least 5% loss in up to 85.1% vs 38.8% · Boehringer Ingelheim release, April 28, 2026.
  • 2026-04-01 · FDA approval · orforglipron — approved for chronic weight management in adults with obesity, or overweight with a weight-related condition; once-daily oral small molecule (non-peptide) · Lilly release, April 1, 2026.
  • 2026-02-23 · REDEFINE 4 headline · CagriSema — 809 adults with overweight or obesity · CagriSema 2.4/2.4 mg vs tirzepatide 15 mg, 84 weeks · 23.0% vs 25.5% (efficacy estimand per sponsor); primary non-inferiority endpoint on weight not met · Novo Nordisk Form 6-K, Feb 23, 2026.
  • 2026-02-03 · VESPER-3 topline · berobenatide (PF-3944) — adults with obesity or overweight without type 2 diabetes, 28 weeks · met primary endpoint with statistically significant placebo-adjusted weight reduction across all dose regimens; sponsor topline · Pfizer release, Feb 2026.
  • 2026-01-27 · CT388-103 Phase 2 topline · enicepatide — 469 adults with obesity or overweight plus a comorbidity, without type 2 diabetes · dose-ranging to 24 mg weekly, 48 weeks · 22.5% placebo-adjusted (efficacy estimand), 18.3% placebo-adjusted (treatment-regimen estimand) at 24 mg; obesity resolution (BMI below 30) in 54% vs 13% placebo · Roche ad hoc announcement, Jan 27, 2026.
  • 2026-01-12 · VENTURE Phase 2 publication · VK2735 — 13-week weekly subcutaneous dosing · up to 14.7% from baseline and up to 13.1% placebo-adjusted · published in Obesity; Viking release, Jan 12, 2026.
  • 2025-12-18 · SURPASS-CVOT publication · tirzepatide — 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease · tirzepatide vs dulaglutide 1.5 mg weekly · MACE-3 hazard ratio 0.92 (95.3% CI 0.83 to 1.01), non-inferiority met, superiority not met · Nicholls et al., NEJM (PMID 41406444).
  • 2025-12 · NDA submission · CagriSema — Novo Nordisk submitted CagriSema for weight management to the FDA on the basis of REDEFINE 1 and REDEFINE 2 · Pharmaceutical Executive, Dec 2025.
  • 2025-11-06 · Eloralintide Phase 2 publication · eloralintide — 263 adults with obesity or overweight and at least one comorbidity, 48 weeks · 1 mg, 3 mg, 6 mg, 9 mg, 6-9 mg and 3-9 mg escalation arms vs placebo · efficacy estimand: -9%, -12%, -18%, -20%, -20%, -16% vs -0.4% placebo; nausea 11% to 64% by arm vs 14% placebo · Billings et al., Lancet (PMID 41207310).
  • 2025-09-30 · Mazdutide: First Approval (review) — review article documenting mazdutide's first approval in China for long-term weight management (June 27, 2025) and the subsequent type 2 diabetes approval · Shirley M, Drugs (PMID 41028652).
  • 2025-09-16 · ATTAIN-1 publication · orforglipron — 3,127 adults with obesity or overweight and a comorbidity, without diabetes · 6 mg, 12 mg or 36 mg daily vs placebo, 72 weeks · treatment-regimen estimand: -7.5% / -8.4% / -11.2% vs -2.1% placebo; adverse-event discontinuation 5.3% to 10.3% vs 2.7% · Wharton et al., NEJM (PMID 40960239). The sponsor's efficacy-estimand figure for 36 mg is 12.4%.
  • 2025-09-14 · STEP UP publication · semaglutide 7.2 mg — 1,407 adults with obesity · 7.2 mg vs 2.4 mg vs placebo weekly, 72 weeks · treatment-policy estimand: -18.7% vs -15.6% vs -3.9%; estimated treatment difference 7.2 mg vs 2.4 mg -3.1 points · Lancet Diabetes & Endocrinology (PMID 40961952). Sponsor-reported trial-product figure for 7.2 mg: 20.7%.
  • 2025-06-23 · MariTide Phase 2 publication · maridebart cafraglutide — 592 adults (465 obesity cohort, 127 obesity plus type 2 diabetes cohort) · monthly fixed doses 140 mg, 280 mg, 420 mg, or 420 mg every 8 weeks, vs placebo, 52 weeks · treatment-policy estimand: -12.3% to -16.2% vs -2.5% (obesity cohort); -8.4% to -12.3% vs -1.7% (obesity-diabetes cohort); HbA1c -1.2 to -1.6 points in the diabetes cohort · Jastreboff et al., NEJM (PMID 40549887).
  • 2025-06-22 · REDEFINE 1 publication · CagriSema — 3,417 adults with obesity or overweight and a comorbidity, without diabetes · cagrilintide 2.4 mg + semaglutide 2.4 mg vs semaglutide alone vs cagrilintide alone vs placebo, 68 weeks · estimated mean change -20.4% vs -3.0% placebo (difference -17.3 points); GI adverse events 79.6% vs 39.9% · Garvey et al., NEJM (PMID 40544433). Sponsor's trial-product figure: 22.7% vs 2.3%.
  • 2025-06-20 · Amycretin sc Phase 1b/2a publication · amycretin — 125 adults aged 18 to 55 with BMI 27.0 to 39.9, single US site · single-ascending, multiple-ascending and dose-response parts, up to 36 weeks · -24.3% at 36 weeks on 60 mg vs -1.1% placebo; -22.0% on 20 mg vs +1.9% placebo · Dahl et al., Lancet (PMID 40550231).
  • 2025-05-25 · GLORY-1 publication · mazdutide — 610 Chinese adults with obesity (BMI at least 28) or overweight (BMI 24 to 28) with a comorbidity · 4 mg or 6 mg weekly vs placebo, 48 weeks · -11.00% (4 mg) / -14.01% (6 mg) vs +0.30% placebo at week 48; at least 15% loss in 35.7% / 49.5% / 2.0%; adverse-event discontinuation 1.5% / 0.5% / 1.0% · Ji et al., NEJM (PMID 40421736).
  • 2025-05-11 · SURMOUNT-5 publication · tirzepatide vs semaglutide — 751 adults with obesity without diabetes, open-label · tirzepatide (10 or 15 mg) vs semaglutide (1.7 or 2.4 mg) weekly, 72 weeks · least-squares mean -20.2% vs -13.7% · Aronne et al., NEJM (PMID 40353578).
  • 2025-04-14 · Development discontinued · danuglipron — Pfizer stopped the oral small-molecule GLP-1 programme after a single participant experienced an asymptomatic, possibly drug-induced liver injury that resolved on discontinuation · STAT News, April 14, 2025; CNBC, April 14, 2025.
  • 2025 (ADA / EASD) · NA-931 Phase 2 · bioglutide — 125 adults with obesity (BMI at least 30, or at least 27 with a comorbidity) · 13-week multiple-ascending-dose, placebo-controlled · up to 13.8% from baseline at 150 mg/day; up to 72% reached at least 12% loss vs about 2% on placebo (sponsor abstracts; no peer-reviewed full publication located) · NCT06564753; Biomed Industries EASD 2025 release.
  • 2023-06-26 · Retatrutide Phase 2 publication · retatrutide — adults with obesity, 48 weeks · 1 mg to 12 mg weekly vs placebo · up to -24.2% at 12 mg · Jastreboff et al., NEJM (PMID 37366315).
  • 2022-06-04 · SURMOUNT-1 publication · tirzepatide — 2,539 adults with obesity or overweight and a comorbidity, without diabetes · 5 mg, 10 mg or 15 mg weekly vs placebo, 72 weeks · treatment-regimen estimand: -15.0% / -19.5% / -20.9% vs -3.1%; at least 20% loss in 50% (10 mg) and 57% (15 mg) vs 3% placebo; adverse-event discontinuation 4.3% / 7.1% / 6.2% vs 2.6% · Jastreboff et al., NEJM (PMID 35658024).
  • 2021-02-10 · STEP 1 publication · semaglutide 2.4 mg — 1,961 adults with overweight or obesity without diabetes · 2.4 mg weekly vs placebo plus lifestyle intervention, 68 weeks · -14.9% vs -2.4%; at least 5% loss in 86.4% vs 31.5%; discontinuation for GI events 4.5% vs 0.8% · Wilding et al., NEJM (PMID 33567185).
  • 2015-07-02 · SCALE Obesity and Prediabetes publication · liraglutide 3.0 mg — 3,731 adults without type 2 diabetes · 3.0 mg daily vs placebo, 56 weeks · -8.0% vs -2.6% · Pi-Sunyer et al., NEJM (PMID 26132939).

How to read trial numbers

Weight-loss percentages from different incretin trials are quoted side by side constantly, and most of those comparisons are wrong because the numbers answer different questions. Three distinctions do most of the work.

Three glowing receptor-like molecular structures connected by golden filaments above a dark reflective surface

Estimand: treatment-regimen vs efficacy. The treatment-regimen (also called treatment-policy or intention-to-treat) estimand averages every randomised participant, including those who stopped the drug, interrupted it, or started another weight-loss therapy. The efficacy (also called trial-product or hypothetical) estimand models what would have happened had everyone stayed on the assigned regimen. The efficacy number is larger by construction in every trial listed here. SURMOUNT-1 reported -20.9% on the treatment-regimen estimand for tirzepatide 15 mg (Jastreboff et al., NEJM 2022, PMID 35658024) while the widely quoted 22.5% is the efficacy estimand for the same arm. SYNCHRONIZE-2 is the clearest recent example: 9.8% treatment-regimen in the NEJM abstract (PMID 42820639), 13.1% efficacy in the sponsor's release, same trial, same day. Journal abstracts tend to lead with treatment-regimen; sponsor toplines tend to lead with efficacy. This page labels every figure.

Placebo-adjusted vs absolute. Some sponsors (Roche for enicepatide, Pfizer for berobenatide, Viking for VK2735) headline the difference between drug and placebo rather than the drug arm's own change from baseline. A 22.5% placebo-adjusted figure and a 22.5% absolute figure are not the same result, and in a trial where placebo gained weight the placebo-adjusted number exceeds the absolute one. Where a release gives only the placebo-adjusted figure, the log says "PA".

Duration and population. A 13-week Phase 2 result (VENTURE, NA-931) is not comparable to a 72- or 80-week Phase 3 result, because in the longer trials listed here (SURMOUNT-1, STEP 1, TRIUMPH-1) weight loss continued well past week 13. Trials in people with type 2 diabetes consistently report smaller percentage losses than trials in people without it: SYNCHRONIZE-1 vs SYNCHRONIZE-2 for survodutide, TRIUMPH-1 vs TRIUMPH-2 for retatrutide, and STEP 1 vs STEP 2 for semaglutide all show the same pattern. The population column in each log entry is there so the comparison can be made on like terms.

Topline vs publication. Sponsor toplines are released months before the peer-reviewed paper and usually report fewer endpoints and a single estimand. When the publication lands, the log gets a second dated entry rather than an edit to the first, so the record shows what was known when.

Compounds covered on this site

Per-compound evidence, dosing-literature and vendor pages. Research-market availability varies by compound; approved pharmaceuticals (semaglutide, tirzepatide, liraglutide) are also sold in research-grade form, which is not the approved product.

Frequently Asked Questions

What does this GLP-1 pipeline tracker cover?
Every incretin-class compound that is either approved or has reported human trial data: GLP-1 agonists, GLP-1/GIP and GLP-1/glucagon dual agonists, triple agonists, amylin agonists and their combinations. Each row carries a dated readout, the estimand the number comes from, and a primary source (journal PMID or sponsor release).
Why do the same trials show two different weight-loss numbers?
Trials report two estimands. The treatment-regimen (treatment-policy) estimand counts everyone randomised, including people who stopped the drug. The efficacy (trial-product) estimand models what would have happened had everyone stayed on treatment. Sponsor headlines usually lead with the efficacy number; journal abstracts usually lead with the treatment-regimen number. This page labels which one each figure is.
Which compound has reported the largest Phase 3 weight loss so far?
Retatrutide. Lilly's TRIUMPH-1 topline (May 21, 2026) reported 28.3% mean weight loss at 80 weeks on the 12 mg dose versus 2.2% on placebo in 2,339 adults with obesity. Retatrutide is investigational; Lilly has said it plans a BLA submission in Q1 2027.
Which incretin compounds are approved as of October 2026?
Semaglutide, tirzepatide and liraglutide are FDA-approved. Orforglipron, an oral small molecule rather than a peptide, was FDA-approved for weight management on April 1, 2026. Mazdutide is approved in China (June 27, 2025) but not in the US. Tirzepatide added a cardiovascular-risk-reduction indication in type 2 diabetes on August 28, 2026.
How often is this page updated?
A dated bullet is appended to the readouts log and the status table row is revised whenever a new topline release, journal publication or regulatory action lands. The lastModified date in the page header shows the most recent revision; earlier entries are never rewritten.
Bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Shop bac water made for peptides

References

  1. Wharton S, le Roux CW, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2). N Engl J Med. 2026 Oct 1. PMID: 42820639
  2. Boehringer Ingelheim. "Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes." GlobeNewswire, October 1, 2026. globenewswire.com
  3. EurekAlert / EASD. "New investigational drug combining eloralintide and tirzepatide (EloraTZP) led to weight loss of up to 23.3% in people living with obesity and type 2 diabetes." September 30, 2026. eurekalert.org
  4. HCPLive. "EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes." October 2026. hcplive.com
  5. Bellido V, le Roux CW, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Sep 29. PMID: 42810372
  6. Viking Therapeutics. "Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens." September 22, 2026. ir.vikingtherapeutics.com
  7. Roche. "Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity." Ad hoc announcement, September 22, 2026. roche.com
  8. Novo Nordisk. "Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial." Company announcement, September 21, 2026. nasdaq.com
  9. Eli Lilly. "FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes." August 28, 2026. investor.lilly.com
  10. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025;393(24):2409-2420. PMID: 41406444
  11. Eli Lilly. "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C." July 23, 2026. investor.lilly.com
  12. Pfizer. "Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide." June 2026. pfizer.com
  13. Pfizer. "Pfizer's Ultra-Long-Acting Injectable GLP-1 RA PF'3944 Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial." February 2026. pfizer.com
  14. Roche. "Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity." Ad hoc announcement, January 27, 2026. roche.com
  15. Eli Lilly. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." May 21, 2026. prnewswire.com
  16. MBX Biosciences. "MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing." May 11, 2026. globenewswire.com
  17. Boehringer Ingelheim. "Results from Phase III SYNCHRONIZE-1 obesity trial." April 28, 2026. boehringer-ingelheim.com
  18. Eli Lilly. "FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions." April 1, 2026. investor.lilly.com
  19. Novo Nordisk. Form 6-K, REDEFINE 4 headline results. February 23, 2026. sec.gov
  20. Viking Therapeutics. "Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity." January 12, 2026. ir.vikingtherapeutics.com
  21. Pharmaceutical Executive. "Novo Nordisk Submits NDA to FDA for CagriSema." December 2025. pharmexec.com
  22. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643. PMID: 41207310
  23. Shirley M. Mazdutide: First Approval. Drugs. 2025;85(12):1621-1627. PMID: 41028652
  24. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806. PMID: 40960239
  25. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PMID: 40961952
  26. Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. PMID: 40549887
  27. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. PMID: 40544433
  28. Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406(10499):149-162. PMID: 40550231
  29. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736
  30. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. PMID: 40353578
  31. STAT News. "Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity." April 14, 2025. statnews.com
  32. CNBC. "Pfizer scraps daily weight loss pill danuglipron after a liver injury." April 14, 2025. cnbc.com
  33. ClinicalTrials.gov. NCT06564753, Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition. clinicaltrials.gov
  34. Biomed Industries, Inc. "Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: an Oral Quadruple Receptor Agonist for Obesity at EASD 2025." FirstWord Pharma. firstwordpharma.com
  35. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
  36. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
  37. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
  38. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015;373(1):11-22. PMID: 26132939